Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
RESEARCH TOOLSreports
Holding SLN?
Track your performance easily
Earnings Data
Report Date
Mar 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.15Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 11, 2019
|% Change Since: -66.40%
|Next Earnings Date:Sep 11, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical progress and strong financial positioning, particularly with the positive Phase II data for Zerlasiran and robust financial milestones. However, the conclusion of the Mallinckrodt collaboration and increased net loss were noted as challenges.Company Guidance
During the Silence Therapeutics earnings call for Q4 2023, the company provided detailed guidance on several key metrics and strategic priorities. Silence Therapeutics reported revenues of GBP 25.4 million for the year ended December 31, 2023, up from GBP 17.5 million in 2022, primarily driven by advancements in partner programs, including AstraZeneca and Hansoh collaborations. The company also highlighted a cash runway extending into 2026, bolstered by a $120 million PIPE financing in February 2024 and an additional $20 million raised in January 2024. Key clinical developments included positive topline Phase II data for Zerlasiran, demonstrating median Lp(a) reductions of 90% or greater, with Phase III planning activities underway. Furthermore, Silence is progressing with its Divesiran program for Polycythemia Vera, targeting a June data release. The company remains committed to advancing its proprietary pipeline and is exploring additional partnering opportunities to support its strategic initiatives.Positive Phase II Data for Zerlasiran
Announced positive top line Phase II data for Zerlasiran in patients with high Lp(a), demonstrating significant Lp(a) reductions of up to 99% durable out to 201 days.
Clinical Progress and Milestones
Completed enrollment in Zerlasiran Phase II program in just 4 months. Achieved $14 million in milestones between AstraZeneca and Hansoh collaborations.
Strong Financial Position
Recorded GBP 25.4 million in revenue versus GBP 17.5 million in 2022. Completed $120 million PIPE financing, increasing cash balance to over $200 million.
Emerging Data for Divesiran
Promising emerging data from the ongoing Phase I study for Divesiran, targeting Polycythemia Vera, with plans to report data by June 2024.
---
SLN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SLN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $15.24 | $13.98 | -8.27% |
| Aug 15, 2024 | $16.26 | $16.77 | +3.14% |
| May 16, 2024 | $22.33 | $22.94 | +2.73% |
| Mar 13, 2024 | $25.90 | $25.61 | -1.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Silence Therapeutics (SLN) report earnings?
Silence Therapeutics (SLN) is schdueled to report earning on Mar 12, 2025, TBA Not Confirmed.
What is Silence Therapeutics (SLN) earnings time?
Silence Therapeutics (SLN) earnings time is at Mar 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SLN EPS forecast?
SLN EPS forecast for the fiscal quarter 2024 (Q4) is -0.12.
---